186 related articles for article (PubMed ID: 29927223)
1. [Nitric Oxide Signaling Pathway and Vascular Activity].
Gao YS
Sheng Li Ke Xue Jin Zhan; 2017 Feb; 48(1):58-62. PubMed ID: 29927223
[TBL] [Abstract][Full Text] [Related]
2. Conventional and Unconventional Mechanisms for Soluble Guanylyl Cyclase Signaling.
Gao Y
J Cardiovasc Pharmacol; 2016 May; 67(5):367-72. PubMed ID: 26452163
[TBL] [Abstract][Full Text] [Related]
3. What is next in nitric oxide research? From cardiovascular system to cancer biology.
Bian K; Murad F
Nitric Oxide; 2014 Dec; 43():3-7. PubMed ID: 25153032
[TBL] [Abstract][Full Text] [Related]
4. The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective.
Krishnan SM; Kraehling JR; Eitner F; Bénardeau A; Sandner P
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890734
[TBL] [Abstract][Full Text] [Related]
5. Redox Mechanisms Influencing cGMP Signaling in Pulmonary Vascular Physiology and Pathophysiology.
Patel D; Lakhkar A; Wolin MS
Adv Exp Med Biol; 2017; 967():227-240. PubMed ID: 29047089
[TBL] [Abstract][Full Text] [Related]
6. Paracrine nitric oxide induces expression of cardiac sarcomeric proteins in adult progenitor cells through soluble guanylyl cyclase/cyclic-guanosine monophosphate and Wnt/β-catenin inhibition.
De Pauw A; Massion P; Sekkali B; Andre E; Dubroca C; Kmecova J; Bouzin C; Friart A; Sibille C; Gilon P; De Mulder D; Esfahani H; Strapart A; Martherus R; Payen V; Sonveaux P; Brouckaert P; Janssens S; Balligand JL
Cardiovasc Res; 2016 Oct; 112(1):478-90. PubMed ID: 27520736
[TBL] [Abstract][Full Text] [Related]
7. Nitric Oxide-cGMP Signaling in Hypertension: Current and Future Options for Pharmacotherapy.
Ataei Ataabadi E; Golshiri K; Jüttner A; Krenning G; Danser AHJ; Roks AJM
Hypertension; 2020 Oct; 76(4):1055-1068. PubMed ID: 32829664
[TBL] [Abstract][Full Text] [Related]
8. A primer for measuring cGMP signaling and cGMP-mediated vascular relaxation.
Straub AC; Beuve A
Nitric Oxide; 2021 Dec; 117():40-45. PubMed ID: 34601102
[TBL] [Abstract][Full Text] [Related]
9. Homogeneous single-label cGMP detection platform for the functional study of nitric oxide-sensitive (soluble) guanylyl cyclases and cGMP-specific phosphodiesterases.
Kopra K; Sharina I; Martin E; Härmä H
Sci Rep; 2020 Oct; 10(1):17469. PubMed ID: 33060787
[TBL] [Abstract][Full Text] [Related]
10. Endurance training upregulates the nitric oxide/soluble guanylyl cyclase/cyclic guanosine 3',5'-monophosphate pathway in the striatum, midbrain and cerebellum of male rats.
Chalimoniuk M; Chrapusta SJ; Lukačova N; Langfort J
Brain Res; 2015 Aug; 1618():29-40. PubMed ID: 26006108
[TBL] [Abstract][Full Text] [Related]
11. The Endothelium-Dependent Nitric Oxide-cGMP Pathway.
Mónica FZ; Bian K; Murad F
Adv Pharmacol; 2016; 77():1-27. PubMed ID: 27451093
[TBL] [Abstract][Full Text] [Related]
12. Receptor-controlled phosphorylation of alpha 1 soluble guanylyl cyclase enhances nitric oxide-dependent cyclic guanosine 5'-monophosphate production in pituitary cells.
Kostic TS; Andric SA; Stojilkovic SS
Mol Endocrinol; 2004 Feb; 18(2):458-70. PubMed ID: 14630997
[TBL] [Abstract][Full Text] [Related]
13. Role of the nitric oxide-soluble guanylyl cyclase pathway in obstructive airway diseases.
Dupont LL; Glynos C; Bracke KR; Brouckaert P; Brusselle GG
Pulm Pharmacol Ther; 2014 Oct; 29(1):1-6. PubMed ID: 25043200
[TBL] [Abstract][Full Text] [Related]
14. Targeted genomic disruption of h-ras induces hypotension through a NO-cGMP-PKG pathway-dependent mechanism.
Chamorro-Jorganes A; Grande MT; Herranz B; Jerkic M; Griera M; Gonzalez-Nuñez M; Santos E; Rodriguez-Puyol D; Lopez-Novoa JM; Rodriguez-Puyol M
Hypertension; 2010 Sep; 56(3):484-9. PubMed ID: 20679183
[TBL] [Abstract][Full Text] [Related]
15. Structure and regulation of soluble guanylate cyclase.
Derbyshire ER; Marletta MA
Annu Rev Biochem; 2012; 81():533-59. PubMed ID: 22404633
[TBL] [Abstract][Full Text] [Related]
16. The importance of the nitric oxide-cGMP pathway in age-related cardiovascular disease: Focus on phosphodiesterase-1 and soluble guanylate cyclase.
Golshiri K; Ataei Ataabadi E; Portilla Fernandez EC; Jan Danser AH; Roks AJM
Basic Clin Pharmacol Toxicol; 2020 Aug; 127(2):67-80. PubMed ID: 31495057
[TBL] [Abstract][Full Text] [Related]
17. Endothelial dysfunction and vascular disease - a 30th anniversary update.
Vanhoutte PM; Shimokawa H; Feletou M; Tang EH
Acta Physiol (Oxf); 2017 Jan; 219(1):22-96. PubMed ID: 26706498
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide/soluble guanylyl cyclase signaling mediates depolarization-induced protection of rat mesencephalic dopaminergic neurons from MPP⁺ cytotoxicity.
Kurauchi Y; Hisatsune A; Isohama Y; Sawa T; Akaike T; Katsuki H
Neuroscience; 2013 Feb; 231():206-15. PubMed ID: 23238575
[TBL] [Abstract][Full Text] [Related]
19. Regulation of Sertoli cell tight junction dynamics in the rat testis via the nitric oxide synthase/soluble guanylate cyclase/3',5'-cyclic guanosine monophosphate/protein kinase G signaling pathway: an in vitro study.
Lee NP; Cheng CY
Endocrinology; 2003 Jul; 144(7):3114-29. PubMed ID: 12810568
[TBL] [Abstract][Full Text] [Related]
20. Molecular variants of soluble guanylyl cyclase affecting cardiovascular risk.
Wobst J; Rumpf PM; Dang TA; Segura-Puimedon M; Erdmann J; Schunkert H
Circ J; 2015; 79(3):463-9. PubMed ID: 25746521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
